Clinical Trials Directory

Trials / Unknown

UnknownNCT05351736

Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

The present longitudinal study aims to investigate the impact of lurasidone treatment in recent-onset psychosis patients. The effects of lurasidone will be studied primarily in terms of structural and myelin modifications, in relation to clinical outcomes, before and after treatment and in healthy controls. Furthermore, neuropsychological tests will be used to evaluate changes in cognitive performance.

Conditions

Interventions

TypeNameDescription
DRUGLurasidoneTreatment with lurasidone

Timeline

Start date
2022-01-26
Primary completion
2024-01-28
Completion
2024-04-28
First posted
2022-04-28
Last updated
2023-03-17

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05351736. Inclusion in this directory is not an endorsement.

Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After (NCT05351736) · Clinical Trials Directory